GlassScriptPhysician profile
Sundararaj Cherala
NPI 1689698359
$1,268.76
in general payments reported to CMS, 2019-2025
21 companies · $15.63 in 2025
The $15.63 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $47.53 · 2023: $386 · 2024: $361 · 2025: $15.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $392.30 | 2023-2024 | Senza |
| Abbvie INC. | $199.65 | 2023-2024 | Ubrelvy, Qulipta, Botox |
| Collegium Pharmaceutical, INC. | $140.00 | 2019-2023 | Xtampza |
| Electronic Waveform Lab, INC. | $77.04 | 2019 | |
| Pacira Therapeutics, INC. | $58.25 | 2019-2020 | |
| Tersera Therapeutics LLC | $50.64 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $43.88 | 2023-2024 | Iovera, Zilretta, Exparel |
| Fidia Pharma USA INC. | $43.29 | 2019 | |
| Sentynl Therapeutics, INC. | $34.29 | 2019 | |
| Zyla Life Sciences, INC. | $29.88 | 2019 | |
| Si-Bone, INC. | $29.34 | 2019 | |
| Shionogi INC | $28.65 | 2019 | |
| Trice Medical, INC. | $25.21 | 2023 | |
| Lilly USA, LLC | $19.85 | 2023 | Emgality, Reyvow |
| Vertiflex, INC. | $17.44 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.63 | 2025 | Inceptiv |
| Spr Therapeutics, INC | $14.93 | 2019 | |
| Boston Scientific Corporation | $14.68 | 2019 | |
| Depuy Synthes Sales INC. | $11.93 | 2019 | |
| Horizon Therapeutics Plc | $11.25 | 2019 | |
| Daiichi Sankyo INC. | $10.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sundararaj Cherala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.